While stent length mismatch is much more common and taken less seriously,diameter mismatch can be more problematic since it looks strikingly odd & ugly .Still, one section of cardiologists believes a little amount of oversizing is safe and good. There is equal opposition to this concept as well. It is not surprising , acquired stent-ectasia of coronary artery during PCI ,has both advantages as well as troubling issues.

The self-adaptive anti-coagulant functional modules within the coating was achieved by thrombin-responsive nanogels. By responding to thrombin, the upstream initiator of coagulation-inflammation, the nanogels dynamically regulated anti-coagulant drug delivery, releasing the therapeutic agents in high thrombotic risk conditions while retaining them in low-risk states. To enhance the blockade of coagulation-inflammation loop, the polyphenol epigallocatechin gallate (EGCG) acted as anti-inflammatory functional modules and participated in coating construction as a cross-linking agent.

Through the detection of biochemical markers, we recorded significant alteration in eNOS, ICAM1, and monocyte attachment in EC grown in microchannel having 60o vessel branching angle which correlated with the lower WSS. The present study highlights the importance of blood vessel branching angle as one of the crucial determining factors in governing atherogenic-endothelial dysfunction.

Cellular mechanobiology is an active field of research that nicely complements the more traditional biochemically-centered view of most biological processes. As we have highlighted throughout this review, mechanical forces are particularly diverse, dynamic, and multifaceted in the vascular system, and these forces play a critical role in regulating vascular physiology and pathology. In light of the fact that many of these forces are borne most directly by the endothelium, elucidating the mechanisms governing EC mechanobiology will enhance our understanding of the etiology of various vascular diseases including atherosclerosis, thrombosis, aneurysm formation, and diabetes.

The model demonstrated high diagnostic accuracy in internal and external validation, outperforming cardiologists in a controlled evaluation and showing consistent performance across different care settings and racial and/or ethnic groups. The models were prospectively evaluated in a clinical trial of patients without previous cardiac imaging, successfully identifying previously undiagnosed heart disease. These findings support the potential of artificial intelligence to expand access to heart disease screening at scale. To enable further development and transparency, we have publicly released model weights and a large, annotated dataset linking heart rhythm data to imaging-based diagnoses.

This is the first conditional approval of three types of domestic high-end implanted medical devices obtained by the U.S. FDA through the pre-market approval (PMA) path, marking an important milestone in the overseas going of domestic coronary stents.According to the announcement, the product is developed based on the theory of "the existence of a time window for arterial and vascular trauma healing" pioneered by Saino Medical International. Its design goal is different from the traditional stent that only inhibits smooth muscle proliferation, but aims to accelerate the patient's trauma healing and functional recovery of vascular endothelium.

This product is intended for catheter-directed thrombectomy treatment in patients with acute high-risk pulmonary embolism (PE) or intermediate-risk PE with clinical deterioration, under one of the following conditions:The presence of thrombus in the main pulmonary artery or major branches, with a high risk of bleeding or contraindications to thrombolytic therapy;The presence of thrombus in the main pulmonary artery or major branches, and the patient has failed thrombolysis or aggressive medical therapy.

In summary, in patients with severe aortic stenosis undergoing TAVR, treatment with colchicine was associated with a lower risk of new-onset atrial fibrillation or atrioventricular conduction disturbances requiring the implantation of a permanent pacemaker at 30 days. In addition, a pre-specified imaging analysis demonstrated a significant reduction in subclinical leaflet thrombosis in patients treated with colchicine as compared to placebo. The trial was however prematurely halted due to a higher rate of stroke in patients treated with colchicine. Confirmatory trials with colchicine or other inflammatory agents, i.e. monoclonal antibodies targeting interleukin1-β or interleukin-6 are warranted to corroborate the effect of anti-inflammatory treatment on the incidence of arrhythmias and subclinical leaflet thrombosis after TAVR.

Coronary aneurysm is defined as a focal dilation of the coronary artery that is at least 1.5 times the diameter of an adjacent normal segment.1 The term coronary aneurysm is often interchangeably used with coronary ectasia, which is arbitrarily defined as a more diffuse dilation of the coronary artery of the same dimensional features as an aneurysm.2 Coronary aneurysms and ectasia are observed in at least 5% of patients who underwent coronary imaging.3 Given the recent expansive use of noninvasive coronary artery imaging, especially coronary computed tomography angiography and magnetic resonance imaging angiography, the detection of coronary aneurysm has become more frequent.4

The first-generation bioresorbable scaffolds (BRS) have been associated with higher rates of device-related adverse outcomes in comparison to everolimus-eluting stents. We aimed to evaluate the efficacy and safety of the thinner-strut (100/125 μm) poly-L-lactic acid-based sirolimus-eluting Firesorb BRS in patients with de novo coronary lesions.

The acquired Vascular Intervention business consists of a portfolio for coronary and peripheral interventions performed in the cath lab and interventional radiology suites. In coronary vascular interventions, Teleflex details that key products include the Pantera Lux drug-coated balloon catheter, the novel PK Papyrus covered coronary stent for acute coronary artery perforations, and the Orsiro Mission drug-eluting stent, an ultrathin drug-eluting stent with differentiated clinical features. For peripheral interventions, the portfolio includes the Passeo-18 Lux peripheral drug-coated balloon catheter, Dynetic-35 balloon-expandable cobalt chromium stent, the Pulsar-18 T3 self-expanding 4F stent, and the Oscar peripheral multifunctional catheter system.

In this study, we propose CPBi, a novel AI-powered IVUS-derived metric, to objectively quantify the diffuseness of atherosclerotic coronary artery disease (ACAD) across the entire vessel. This approach provides insight into the distribution of atherosclerosis without requiring hyperemic pressure wire pullback and supports clinical decision-making for optimal stent strategy.

Leukocyte-shed sCD31 unmasks coronary disease in low-risk outliers and provides source-specific inflammatory signatures of vulnerable plaques. The differential pattern of sCD31 forms based on risk burden suggests distinct pathophysiological mechanisms driving atherosclerosis in different patient populations, addressing a critical gap in current risk assessment.

This study estimated increases of hospital LOS and costs for patients with severe surgical bleeding complications in France. Hospitalisations longer than the average LOS across all DRGs indicated significant costs associated with severe post-surgical bleeding. Awareness of the clinical and economic consequences of severe post-surgical bleeding provides an important framework when evaluating blood conservation strategies.

Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it is inevitably associated with increased bleeding. The continuous refinement in stent technologies, together with the high incidence of ischaemic recurrences after PCI and the understanding of prognostic implications associated with bleeding, have led to a substantial evolution in antiplatelet treatment regimens over the past decades.

CD31 signaling promotes the switching of proinflammatory macrophages to the reparative phenotype and favors the healing of experimental dissected aortas. Treatment with a drug-suitable CD31 agonist may facilitate the clinical management of ADIM.

Biotronik has announced the enrolment of the first patient in the Leave Nothing Behind-trial, which aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with resorbable magnesium scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI).

Clot-induced blockage in arteries or veins can cause severe medical conditions. Mechanical thrombectomy is a minimally invasive technique used to treat ischaemic stroke, myocardial infarction, pulmonary embolism and peripheral vascular disease by removing clots through aspiration, stent retriever or cutting mechanisms. However, current mechanical thrombectomy methods fail to remove clots in 10–30% of patients, especially in the case of large, fibrin-rich clots. These methods can also rupture and fragment clots, causing distal emboli and poor outcomes. To overcome these challenges, we develop the milli-spinner thrombectomy, which uses a simple yet innovative mechanics concept to modify the clot’s microstructure, facilitating its removal.

In patients who had undergone PCI and discontinued DAPT, at a follow-up of about 5.5 years, P2Y12 inhibitor monotherapy with ticagrelor or clopidogrel was associated with lower MACCE, owing to reduced rates of myocardial infarction and stroke compared with aspirin monotherapy, without a concurrent increased risk of major bleeding.

Thrombus treatment remains a significant challenge, primarily due to factors such as the short half-life of thrombolytic agents, suboptimal drug utilization, and limited therapeutic efficacy. In this study, we developed a platelet membrane-camouflaged bioactive glass nanoparticles (BGs) as drug carriers to load thrombolytic agent urokinase (UK) and anticoagulant drug tirofiban (TF).